drugset
drugset / Trial / NCT00737113

Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant

NCT00737113 ↗

Phase 1 Terminated 14 enrolled Mitchell Horwitz, MD Pfizer · collab
NaSingle-groupOpen-label

Summary

The primary objective of this study is to define the safety and efficacy of recombinant human growth hormone (rh-GH, Genotropin) in a patients undergoing allogeneic transplantation.

Timeline

Start
2008-09
Primary completion
2012-05
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.02 mg/kg Subcutaneous

Indications

disease related to hematopoietic stem cell transplant